In addition, as mentioned above, a growing number of studies have started to examine the impact of AXL on conventional therapy, e.g., AXL inhibitors in combination with chemotherapy, targeted therapies, and especially immunotherapy, and these advances have increased our understanding of tumor biology, tumor progression, and the tumor immune microenvironment, showing promising prospect. The gene discussed is AXL; the disease is neoplasm.